Mesenchymal Stem Cell Therapy for Alzheimer's Disease

Area of Science:

• Neuroscience
• Regenerative Medicine
• Stem Cell Biology

Background:

• Alzheimer's disease (AD) is a leading cause of dementia, characterized by neurodegeneration and cognitive decline.
• Current AD treatments manage symptoms but do not halt disease progression.
• Mesenchymal stem cells (MSCs) demonstrate neuroregenerative and disease-inhibiting potential in AD models.

Purpose of the Study:

• To review preclinical research on MSC-based therapies for Alzheimer's disease.
• To compile findings from transgenic mouse models and clinical trials of MSC therapy.
• To evaluate the potential of MSCs and their extracellular vesicles (EVs) in altering AD pathology.

Main Methods:

• Review of preclinical studies using transgenic mouse models of AD.
• Analysis of clinical trial data for MSC-based therapies in AD patients.
• Investigation of the immunomodulatory and neuroprotective effects of MSC-derived EVs.

Main Results:

• MSCs exhibit neuroregenerative capabilities and can inhibit AD progression.
• Extracellular vesicles (EVs) from cytokine-preconditioned MSCs show immunomodulatory and neuroprotective effects.
• Evidence suggests MSC-based therapies may offer a novel approach to modifying AD pathology.

Conclusions:

• MSC-based therapies, including the use of EVs, represent a promising avenue for Alzheimer's disease treatment.
• Further research and clinical trials are warranted to fully elucidate the therapeutic potential of MSCs in AD.
• Targeting neuroregeneration and neuroprotection with MSCs could offer disease-modifying benefits for Alzheimer's patients.